1781 Stock Overview
Health & Life Co., Ltd. manufactures and sells products for cardiovascular disease, in-vitro diagnostics, and respiratory care worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Health & Life Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$15.60 |
| 52 Week High | NT$19.95 |
| 52 Week Low | NT$11.25 |
| Beta | 0.90 |
| 1 Month Change | 0% |
| 3 Month Change | 1.30% |
| 1 Year Change | 7.96% |
| 3 Year Change | -28.28% |
| 5 Year Change | 54.46% |
| Change since IPO | -86.29% |
Recent News & Updates
Shareholder Returns
| 1781 | TW Medical Equipment | TW Market | |
|---|---|---|---|
| 7D | -2.8% | 1.6% | -2.3% |
| 1Y | 8.0% | 7.0% | 27.2% |
Return vs Industry: 1781 exceeded the TW Medical Equipment industry which returned 5.6% over the past year.
Return vs Market: 1781 underperformed the TW Market which returned 29.2% over the past year.
Price Volatility
| 1781 volatility | |
|---|---|
| 1781 Average Weekly Movement | 5.8% |
| Medical Equipment Industry Average Movement | 4.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.7% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 1781 has not had significant price volatility in the past 3 months.
Volatility Over Time: 1781's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | n/a | n/a | www.healthandlife.com.tw |
Health & Life Co., Ltd. manufactures and sells products for cardiovascular disease, in-vitro diagnostics, and respiratory care worldwide. It offers vibrating mesh nebulizers, blood pressure monitor products, IR thermometers, and hearing aid devices. The company was founded in 1996 and is based in New Taipei City, Taiwan.
Health & Life Co., Ltd. Fundamentals Summary
| 1781 fundamental statistics | |
|---|---|
| Market cap | NT$739.56m |
| Earnings (TTM) | -NT$33.23m |
| Revenue (TTM) | NT$601.17m |
1.2x
P/S Ratio-22.3x
P/E RatioIs 1781 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1781 income statement (TTM) | |
|---|---|
| Revenue | NT$601.17m |
| Cost of Revenue | NT$508.07m |
| Gross Profit | NT$93.11m |
| Other Expenses | NT$126.33m |
| Earnings | -NT$33.23m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.70 |
| Gross Margin | 15.49% |
| Net Profit Margin | -5.53% |
| Debt/Equity Ratio | 28.9% |
How did 1781 perform over the long term?
See historical performance and comparison